The IRA Phase 2: What 2026 Price Negotiations Mean for Innovators, Biosimilars, and Global Launch Strategy
The Inflation Reduction Act (IRA) continues to reshape the U.S. pharmaceutical market. After the first list of 10 Medicare Part D drugs entered negotiations in 2023, the clock is now ticking toward Phase 2, when the next set of drugs will be named for 2026 price-setting. What initially felt like a distant policy shift is becoming a commercial reality, and the implications go far beyond U.S. Medicare pricing. For innovative drug makers, biosimilar developers, and even companies shaping launch plans in Europe, Asia, and emerging markets, Phase 2 is signalling a new era: one where U.S. price controls create ripple effects across global strategy. A Turning Point: Why 2026 Matters Unlike the first negotiation wave, Phase 2 introduces new layers of complexity not just because more therapies will be included, but also because the selection criteria expand to include Part B drugs and biologics. This means monoclonal antibodies, oncology blockbusters, and multi-indication therapies are li...